Seegene

Seegene Net Debt

The Net Debt of Seegene (096530.KQ) as of Nov 4, 2026 is 232.00 M KRW. In the previous year, Net Debt was 763.48 M KRW — a change of -69.61% (lower).

Net Debt

232.00 MKRW

YoY

-69.61%

Last updated:

Net Debt of Seegene is 2025 232.00 M KRW. Net Debt of Seegene was 2024 763.48 M KRW. It decreases by -69.61% lower compared to the previous year.

The Seegene Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-33.91 B KRW
Jan 1, 2019
-51.00 B KRW
Jan 1, 2020
-218.22 B KRW
Jan 1, 2021
-314.39 B KRW
Jan 1, 2022
-444.59 B KRW
Jan 1, 2023
1.42 B KRW
Jan 1, 2024
763.48 M KRW
Jan 1, 2025
232.00 M KRW
The Seegene Net Debt history
YEARNet DebtYoY
232.00 MKRW-69.61%
763.48 MKRW-46.36%
1.42 BKRW-100.32%
-444.59 BKRW+41.42%
-314.39 BKRW+44.07%
-218.22 BKRW+327.90%
-51.00 BKRW+50.40%
-33.91 BKRW+47.72%
-22.95 BKRW-32.35%
-33.93 BKRW+9.56%
-30.97 BKRW-200.88%
30.70 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Net Debt of Seegene is 232.00 M KRW in 2025.

Net Debt of Seegene changed from 763.48 M KRW to 232.00 M KRW, representing a -69.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Seegene since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Seegene

All Key Metrics — Seegene